Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease (DINE-CD)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03058679 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : May 12, 2020
|
Sponsor:
University of Pennsylvania
Collaborators:
Patient-Centered Outcomes Research Institute
Crohn's and Colitis Foundation
University of North Carolina, Chapel Hill
Information provided by (Responsible Party):
University of Pennsylvania
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and bowel inflammation that characterize this debilitating disease.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Crohn Disease | Other: Diet | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 194 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease |
| Actual Study Start Date : | September 29, 2017 |
| Actual Primary Completion Date : | March 1, 2020 |
| Estimated Study Completion Date : | July 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Crohn disease
MedlinePlus related topics:
Crohn's Disease
| Arm | Intervention/treatment |
|---|---|
| Experimental: Specific Carbohydrate Diet |
Other: Diet
food for the diet will be provided to the participants for 6 weeks |
| Active Comparator: Mediterranean Style Diet |
Other: Diet
food for the diet will be provided to the participants for 6 weeks |
Primary Outcome Measures :
- Symptomatic remission [ Time Frame: 6 weeks ]Assessed by Short Crohn's Disease Activity Index (sCDAI) - diarrhea, abdominal pain and general well being
- Reduction in bowel inflammation [ Time Frame: 6 weeks ]Calprotectin <250 mcg/gm and >50% reduction from baseline
Secondary Outcome Measures :
- Clinical remission [ Time Frame: 6 weeks ]Assessed by the Harvey Bradshaw Index
- Reduction in systemic inflammation [ Time Frame: 6 weeks ]hsCRP < 5mg/L >50% reduction from baseline
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
- Age ≥18
- Documented diagnosis of Crohn's disease
- sCDAI score >175
- Documentation of receipt of a baseline stool sample by the data coordinating center and hsCRP.
- Access to a computer with internet and the ability to complete daily online surveys
- Capable of providing consent to participate
- Able to receive weekly food shipments delivered every Friday for 6 weeks
Exclusion Criteria
- Pregnancy
- sCDAI >400
- Hospitalized patients
- Anticipated need for surgery within 6 weeks of randomization
- Use of the Specific Carbohydrate Diet within 4 weeks of screening
- Start or change*** dose of thiopurines (azathioprine and 6-MP), methotrexate, natalizumab, or vedolizumab within 12 weeks prior to screening
- Start or change*** dose of anti-TNF agents (including infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), golimumab (Simponi) or ustekinumab within 8 weeks prior to screening.
- Start or change in dose of any 5-ASA medications within 2 weeks of screening.
- Start or change dose of corticosteroids within 1 week of screening or a dose >20mg/day prednisone or equivalent*
- Use of antibiotics (other than topical formulations) for any reason within 2 weeks prior to screening
- Known symptomatic intestinal stricture.
- Presence of an ostomy
- Baseline stool frequency >4 bowel movements/day when well
- BMI <16
- BMI ≥40
- Celiac disease
- Documented C difficile colitis within four weeks of screening
- Diabetes Mellitus requiring medication
- Albumin<2.0mg/dl, within 4 weeks of screening (if tested as part of routine clinical care)
- Known allergy to tree nuts or peanuts
- Other conditions that would be a contraindication to any of the study diets or preclude the participant from completing the study.
-
Currently participating in another clinical trial of a drug to treat IBD or a dietary therapy for any indication.
-
Patients may continue these medications at stable dose for the first six weeks and budesonide may be used at any dose. After the 6th week in the study, patients may taper their steroid dose. The study will provide a recommended taper schedule.
- Loading/induction doses of biologic type medication will be considered a stable doses. ***Exception for treatment failures: if a subject is determined to fail on any of the following standard lines of treatment at the treating investigator's discretion, subjects may screen for study intervention based upon the following wash out periods: 4 weeks for thiopurine and methotrexate and 8 weeks for natalizumab, vedolizumab, anti-TNF, or ustekinumab.
-
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03058679
Locations
Show 35 study locations
Sponsors and Collaborators
University of Pennsylvania
Patient-Centered Outcomes Research Institute
Crohn's and Colitis Foundation
University of North Carolina, Chapel Hill
Investigators
| Principal Investigator: | James D Lewis, MD, MSCE | University of Pennsylvania |
| Responsible Party: | University of Pennsylvania |
| ClinicalTrials.gov Identifier: | NCT03058679 |
| Other Study ID Numbers: |
825907 |
| First Posted: | February 23, 2017 Key Record Dates |
| Last Update Posted: | May 12, 2020 |
| Last Verified: | May 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by University of Pennsylvania:
|
diet specific carbohydrate diet Mediterranean style diet randomized controlled trial |
Additional relevant MeSH terms:
|
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis |
Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |